Özgür has led more than 300 transactions with valuations of $100m-10bn+, working with private equity & venture capital investors
Stablepharma has announced Özgür Tuncer will be appointed CEO.
Dr Bruce Roser MB BS, PhD, FRCPA, founder and chairman of Stablepharma said: “As the company strategically transitions from the R&D and product development stage to the commercial stage, Özgür’s appointment with his extensive pharmaceutical background, makes him the ideal and logical candidate to drive the business forward and form key strategic alliances. This is a very exciting time for Stablepharma and marks an important step change for the company.”
Özgür has more than two decades of experience in the biopharmaceutical industry with expertise in leadership, strategy, M&A and investments. He joins Stablepharma from his recent role as Global VP of IQVIA, leading the company’s financial investors practice. Özgür has led more than 300 transactions with valuations of $100m-10bn+, working with private equity & venture capital investors. Previously, Özgür worked for 6 years in the USA for Pfizer, overseeing portfolio strategy and investments in infectious diseases.
Nick Child, co-founder at Stablepharma: “I first met Özgür 4 years ago, and have enjoyed working with him since we appointed him as Chair of our Advisory Board, where his expertise has added considerable value to our strategic planning process. I’m delighted that he has accepted the CEO role; bringing decades of Pharma Industry experience that will be pivotal in taking Stablepharma to the next level, to include leading a Series A funding round later this year.”
“I am very excited to be taking the role of CEO of Stablepharma and continuing to work with the team,” said Tuncer. “I believe Stablepharma has industry leading technology that uniquely positions the company to capitalize on the ever-increasing need for thermostable vaccines, that will ultimately deliver global humanitarian benefits.”
‘’The current COVID pandemic reminded all of us just how vital it is to provide access to vaccines without cold chain limitations. We believe that our StablevaX platform has the capacity to deliver on that so that everyone, everywhere can have access to life saving vaccines.”